Fixing common blood disorder would make kidney transplants more successful

December 22, 2011 in Other

Correcting anemia, a red blood cell deficiency, can preserve kidney function in many kidney transplant recipients, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results indicate that aggressively treating anemia may help save the kidneys—and possibly the lives—of many transplant recipients.

Anemia commonly arises in patients with disease because the kidneys secrete most of the hormone erythropoietin that stimulates production. is also a common complication of kidney transplantation, with a prevalence of 25% to 40% after the first year.

Gabriel Choukroun, MD, PhD (CHU Amiens in France) and his colleagues initiated the Correction of Anemia and PRogression of Renal Insufficiency in Transplant patients (CAPRIT) study to see if the drug epoetin beta (a synthetic form of erythropoietin) could help preserve in kidney transplant recipients with anemia. Specifically, the investigators tested whether completely correcting anemia (by normalizing levels of hemoglobin, a blood component that carries oxygen) is better than partially correcting anemia.

During the study, 63 kidney transplant recipients took epoetin beta so that their hemoglobin levels remained in the normal range of 13.0 to 15.0 g/dL, while 62 patients took epoetin beta so that their hemoglobin levels hovered at a lower concentration of 10.5 to 11.5 g/dL.

Among the major findings after patients were treated for two years:

  • 4.8% of patients with completely corrected anemia developed kidney failure, compared with 21% of patients with partially corrected anemia.
  • 94.6% of transplanted kidneys in patients with completely corrected anemia were functional, compared with 80% in patients with partially corrected anemia.
  • Patients with completely corrected anemia experienced a significant improvement in quality of life at six and 12 months after starting therapy.
"This study shows that correction of anemia in with anemia slows the progression of kidney failure and improves survival of transplanted kidneys," said Dr. Choukroun. Additional studies are needed to determine whether this also prolongs patients' lives.

More information: The article, entitled "Correction of Post-Kidney Transplant Anemia Reduces Progression of Allograft Nephropathy," will appear online on December 22, 2011, doi: 10.1681/ASN.2011060546

Provided by American Society of Nephrology search and more info website

not rated yet  

Filter


Move the slider to adjust rank threshold, so that you can hide some of the comments.


Display comments: newest first

ironjustice
Dec 23, 2011

Rank: not rated yet
Isn't it amazing that the same hemoglobin which KILLS kidney disease patients, 12.5 , at an even HIGHER number RESCUES kidney transplant patients? One might wonder whether there are any 'conflicts of interest' here. Pharmaceutical companies which supply this very expensive drug erythropoietin ? Erythropoietin USED to be the 'apple of everyones eye' BUT when it was discovered it was killing everyone it went from ten to one in sales.
Rank not rated yet
Relevant PhysicsForums posts

More news stories

Flesh-eating disease victim gets prosthetic hands

(AP)—A woman who lost both hands, her left leg and right foot after contracting a flesh-eating disease has been fitted with prosthetic hands.

Other created May 18, 2013 | popularity not rated yet | comments 0

Illinois Senate approves medical marijuana bill

(AP)—Medical marijuana use in Illinois is now in Gov. Pat Quinn's hands after the state Senate approved legislation.

Other created May 17, 2013 | popularity 5 / 5 (1) | comments 0

Nigerian court jails two over killer teething drug

A Nigerian court on Friday sentenced two officials from a pharmaceutical company to seven years in prison over the sale of an adulterated teething drug which killed 84 babies in 2008.

Other created May 17, 2013 | popularity not rated yet | comments 0

Many patients would switch doc to cut health care costs

(HealthDay)—Many Americans feel that keeping out-of-pocket health care costs is more important than staying with the same primary care physician.

Other created May 17, 2013 | popularity not rated yet | comments 0

Cultural attitudes impede organ donations in China

(AP)—China is phasing out its reliance on executed prisoners for donated organs, but an architect of the country's transplant system said Friday that ingrained cultural attitudes are impeding the rise of ...

Other created May 17, 2013 | popularity not rated yet | comments 0


Researchers identify a potential new risk for sleep apnea: Asthma

Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...

Study finds that sleep apnea and Alzheimer's are linked

A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.

Ginger compounds may be effective in treating asthma symptoms

Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the ...

Computational tool translates complex data into simplified 2-dimensional images

In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...

New theory on genesis of osteoarthritis comes with successful therapy in mice

Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...

'Gap' for HIV vaccine efforts after latest setback

The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.